On Friday, May 7, 2010, Teva Pharmaceuticals USA announced that the
U.S. Food and Drug Administration has granted final approval for the
Company’s Abbreviated New Drug Application (“ANDA”) for Buprenorphine
HCl Sublingual Tablets 2 & 8 mg. Teva’s Buprenorphine HCl Sublingual Tablets
are the AB-rated generic equivalent of Reckitt Benckiser’s Subutex® and are
indicated for the treatment of narcotic addiction.
Teva intends the commercial launch to occur later this month. To learn more
about Buprenorphine HCl Sublingual Tablets prescribing information, please call 1-800-227-7522.
